His main research focuses on the recurrence mechanism and intervention strategies of ischemic cerebrovascular disease. Discovered key molecular mechanisms of cerebrovascular disease recurrence, pioneered the "CHANCE" dual antiplatelet therapy, which reduced the risk of recurrence in patients by 32%, and developed personalized precision medicine based on drug-genetic interactions that further reduced recurrence risks by 20%. He discovered the residual risk mechanism of recurrent cerebrovascular disease, developed therapeutic drugs targeting new mechanisms and targets, and achieved industrialization. He published over 200 papers as first or corresponding author in prestigious journals such as NEJM, LANCET, JAMA, BMJ, etc., involved in the design and served as the principal investigator of large-scale clinical studies, accounting for 30% of the total published cerebrovascular disease research articles in leading medical journal NEJM. Additionally, he received two second-class National Science and Technology Progress Awards and two first-class provincial and ministerial awards as the first author. He has been awarded the National Innovation Medal, the Tan Jiazhen Clinical Medicine Award, the Outstanding Professional and Technical Talent title, the World Stroke Organization (WSO) Chair Award - the highest achievement award, and the 2022 "Ho Leung Ho Lee Foundation Science and Technological Progress Award".

Prof. Wang is currently the president of Beijing Tiantan Hospital, Capital Medical University. He also acts as the Director of the National Medical Quality Control Center for Neurological Diseases, Vice Director of the Clinical Medical Research Center for Neurological Diseases, Director of the Beijing Advanced Innovation Center for Brain Protection, President of the Chinese Stroke Association, Chairman of the Neurology Branch of the Chinese Medical Association, and Editor-in-Chief of the Stroke & Vascular Neurology (SVN) journal. Additionally, he serves as the Chief Expert in the field of cerebrovascular diseases for the National Twelfth Five-Year Science and Technology Support Program and the Chief Expert in the field of non-communicable diseases for the National Thirteenth Five-Year Key R&D Program, member of the cross projects expert group for the National Major New Drug Development Science and Technology Major Project.